Skip to content

Study on the evaluation of clinical effect and applicability of optimized Yifei moxibustion in the treatment of COPD based on human surface temperature real-time monitoring system

Optimization study of Yifei moxibustion for COPD based on "moxibustion volume, moxibustion temperature, moxibustion sensation, and moxibustion effect".

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080555
Enrollment
Unknown
Registered
2024-02-01
Start date
2023-05-13
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Group H:2cm thickness cashmere, 2cm ginger paste, 90min treatment time
Group A:3cm thickness cashmere, 2.5cm ginger paste, 60min treatment time
Group B:3cm thickness cashmere, 2.5cm ginger paste, 90min treatment time
Group C:2cm thickness cashmere, 2.5cm ginger paste, 60min treatment time
Group D:2cm thickness cashmere, 2.5cm ginger paste, 90min treatment time
Group E:3cm thickness cashmere, 2cm ginger paste, 60min treatment time
Group F:3cm thickness cashmere, 2cm ginger paste, 90min treatment time
Group G:2cm thickness cashmere, 2cm ginger paste, 60min treatment time

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with stable COPD who meet the above diagnostic criteria; 2. Meet the TCM syndrome differentiation criteria of lung-qi deficiency, lung-qi deficiency, and lung-kidney deficiency; 3. Age 18-80 years old; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating patients; 2. Patients with cognitive impairment, confusion, dementia, and various mental illnesses; 3. Patients with unstable angina and acute myocardial infarction; 4. Previous history of syncope after exercise, osteoarthritis affecting exercise; 5. Patients with pneumothorax, pleural effusion, pulmonary embolism, and tumor; 6. Those who are known to be allergic to the ingredients of moxibustion powder.

Design outcomes

Primary

MeasureTime frame
6-minute walk distance;

Secondary

MeasureTime frame
Modified version of the British Medical Research Council dyspnea scale;Lung function;Clinical signs and symptoms questionnaire;Body surface temperature;numerical rating scale;COPD Assessment Test;Modified COPD patient reported outcome scale;Modified Efficacy satisfaction questionnaire for COPD patients;Number of exacerbations;Moxibustion Sensation Evaluation;

Countries

China

Contacts

Public ContactYang Xie

The First Affiliated Hospital of Henan University of Chinese Medicine

xieyanghn@163.com+86 135 2662 1325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026